CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program…
| Quarter | Revenue | YoY | Net Income | EPS (dil.) | YoY | Gross Margin | Op. Margin |
|---|---|---|---|---|---|---|---|
| Q1 2026 Mar 2026 | $1.0M | — | $-122.9M | $-1.28 | +19.0% | -4,494.9% | -13,024.8% |
| Q4 2025 Dec 2025 | $0 | -100.0% | $-130.6M | $-1.37 | -211.4% | — | — |
| Q3 2025 Sep 2025 | $0 | — | $-106.4M | $-1.17 | — | — | — |
| Q2 2025 Jun 2025 | $0 | — | $-208.5M | $-2.40 | — | — | — |
| Q1 2025 Mar 2025 | $0 | — | $-136.0M | $-1.58 | — | — | — |
Data from Yahoo Finance. YoY compares the same quarter of the prior fiscal year.
Can the CRISPR Therapeutics Pipeline in cardiology turn today’s modest gene-editing revenues into a multi-billion-dollar growth story? Maik Kemper Editor in Chief Conclusion In summary, the cardiology-focused CRISPR…